Collaboration

Svenska

Animal Health Trust (AHT), Newmarket, UK, www.aht.uk
AHT is an independent trust working within animal health since more than 50 years and has more than 200 employees, including research staff and clinicians. AHT is one of the few institutions in Europe where experimental infections classified as high risk to the environment can be performed. At the Allen Centre facility, Intervacc has tested its prototype vaccines in horses.

The Swedish University of Agricultural Sciences (SLU), Uppsala, www.slu.se

Karolinska Institutet (KI), Stockholm, www.ki.se

Isconova AB, Uppsala, www.isconova.se
Isconova has developed a patented technology that enhances the effect of vaccines (adjuvants). The technique is based on different immune-stimulating components, saponins, which are extracted from the tree Quillaja saponaria. Following purification the immune-stimulating components produce different complexes named iscomes. Iscomes are included in several authorized vaccines amongst one of which is a vaccine against horse influensa. Intervacc has an agreement with Isconova to use the iscome technology in its strangles vaccine.

SBL Vaccine, Solna, www.sblvaccines.se
SBL Vaccine is the leading distributor of human vaccines in Sweden. The company’s expertise emanates from a long tradition of medical microbiological research and development. SBL Vaccine collaborates with both Swedish and international research teams and vaccine companies. The company is a world leader on prophylactic treatment of tourist diarrhea. SBL Vaccine is a part of the Crucell group. Intervacc has initiated collaboration with SBL Vaccine for collaboration with SBL Vaccine for up-scaling and production of the active components of the strangles vaccine.

Nordvacc Läkemedel AB, Stockholm, www.nordvacc.se